Jeil Pharmaceutical Co.,Ltd (KRX:271980)

Revenue by Segment

Financials in millions KRW. Fiscal year is January - December.

Fiscal Year	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020	FY 2019
Period Ending	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020	Dec 31, 2019
Pharmaceutical Business Division			705.34B	722.23B	700.69B	691.32B	671.41B
Pharmaceutical Business Division Growth			-2.34%	3.07%	1.36%	2.97%	-
Research & Developent Division			21.06B	-	-	-	-
Total			726.39B	722.23B	700.69B	691.32B	671.41B
Total Growth			0.58%	3.07%	1.36%	2.97%	-

Revenue by Geography

Financials in millions KRW. Fiscal year is January - December.

Fiscal Year	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020	FY 2019
Period Ending	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020	Dec 31, 2019
South Korea			684.74B	696.77B	679.37B	661.45B	638.31B
South Korea Growth			-1.73%	2.56%	2.71%	3.63%	-
Overseas			41.65B	25.46B	21.32B	29.87B	33.10B
Overseas Growth			63.59%	19.43%	-28.64%	-9.73%	-
Total			726.39B	722.23B	700.69B	691.32B	671.41B
Total Growth			0.58%	3.07%	1.36%	2.97%	-

Data Source: S&P Global Market Intelligence Last updated: Mar 31, 2026

Financial data is provided by S&P Global Market Intelligence and updates within hours after each earnings release, which is every three months for this company.

Update frequency:

Quarterly

Last checked:

Jun 23, 2026

Data Sources Report a data error